Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia

Therapeutic Advances in Hematology

Volumn 3, Issue 4, 2012, Pages 237-251

  Bakchoul, Tamam ^a   Greinacher, Andreas ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

heparin; thrombocytopenia; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; ARGATROBAN; BEVALIRUDIN; DABIGATRAN; DANAPAROID; DESULFATOHIRUDIN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRUDIN DERIVATIVE; HIRULOG; LEPIRUDIN; PROSTACYCLIN; RIVAROXABAN; TIROFIBAN; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANTIBODY DETECTION; BLEEDING; DEEP VEIN THROMBOSIS; GRAFT OCCLUSION; HEART ATRIUM FIBRILLATION; HEART SURGERY; HEMODIALYSIS; HOSPITAL PATIENT; HUMAN; IMMUNOASSAY; INJECTION SITE REACTION; LABORATORY TEST; OUTPATIENT; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SKIN NECROSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS;

EID: 84993705123     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620712443537     Document Type: Article

References (93)

1. Ağar Ç. de Groot P. Marquart J.A. Meijers J.C. (2011) Evolutionary conservation of the lipopolysaccharide binding site of β2-glycoprotein I. Thromb Haemost 106: 1069-1075.
2. Alatri A. Armstrong A.E. Greinacher A. Koster A. Kozek-Langenecker S.A. Lance M.D. et al. (2011) Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - An European Perspective. Thromb Res, in press, http://www.ncbi.nlm.nih.gov/pubmed/22178575.
3. Althaus K. Strobel U. Warkentin T.E. Greinacher A. (2011) Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. Thromb Res 128: 256–260.
4. Amiral J. Bridey F. Dreyfus M. Vissoc A.M. Fressinaud E. Wolf M. et al. (1992) Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 68: 95–96.
5. Amiral J. Bridey F. Wolf M. Boyer-Neumann C. Fressinaud E. Vissac A.M. et al. (1995) Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 73: 21–28.
6. Arepally G.M. Ortel T.L. (2006) Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355: 809–817.
7. Asmis L.M. Segal J.B. Plantinga L.C. Fink N.E. Kerman J.S. Kickler T.S. et al. (2008) Heparin-induced antibodies and cardiovascular risk in patients on dialysis. Thromb Haemost 100: 498–504.
8. Bakchoul T. Giptner A. Bein G. Santoso S. Sachs U.J. (2011) Performance characteristics of two commercially available IgG-specific immunoassays in the assessment of heparin-induced thrombocytopenia (HIT). Thromb Res 127: 345–348.
9. Bakchoul T. Giptner A. Najaoui A. Bein G. Santoso S. Sachs U.J. (2009) Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 7: 1260–1265.
10. Baron S.J. Yeh R.W. Cruz-Gonzalez I. Healy J.L. Pomerantsev E. Garasic J. et al. (2008) Efficacy and safety of argatroban in patients with heparin induced thrombocytopenia undergoing endovascular intervention for peripheral arterial disease. Catheter Cardiovasc Interv 72: 116–120.
11. Bauer K.A. (2011) Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 9(Suppl. 1): 12–19.
12. Bounameaux C. Boehlen F. Membre A. Genne D. Pouplard C. Regnault V. et al. (2007) Heparin-induced thrombocytopenia associated with interleukin-8-dependent platelet activation in a patient with antiphospholipid syndrome. Eur J Haematol 79: 550–553.
13. Carlsson L.E. Lubenow N. Blumentritt C. Kempf R. Papenberg S. Schroder W. et al. (2003) Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics 13: 253–258.
14. Carrier M. Knoll G.A. Kovacs M.J. Moore J.C. Fergusson D. Rodger M.A. (2007) The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis. Thromb Res 120: 215–220.
15. Castelli R. Cassinerio E. Cappellini M.D. Porro F. Graziadei G. Fabris F. (2007) Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects. Cardiovasc Hematol Disord Drug Targets 7: 153–162.
16. Chong B.H. Ismail F. Cade J. Gallus A.S. Gordon S. Chesterman C.N. (1989) Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 73: 1592–1596.
17. Cruz-Gonzalez I. Sanchez-Ledesma M. Baron S.J. Healy J.L. Watanabe H. Osakabe M. et al. (2008) Efficacy and safety of argatroban with or without glycoprotein IIb / IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome. J Thromb Thrombolysis 25: 214–218.
18. Cuker A. Arepally G. Crowther M.A. Rice L. Datko F. Hook K. et al. (2010) The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost 8: 2642–2650.
19. de Denus S. Spinler S.A. (2002) Clinical monitoring of direct thrombin inhibitors using the ecarin clotting time. Pharmacotherapy 22: 433–435.
20. de Loughery T.G. (2011) Practical aspects of the oral new anticoagulants. Am J Hematol 86: 586–590.
21. Eichler P. Raschke R. Lubenow N. Meyer O. Schwind P. Greinacher A. (2002) The new ID-heparin/PF4 antibody test for rapid detection of heparin-induced antibodies in comparison with functional and antigenic assays. Br J Haematol 116: 887–891.
22. Goldfarb M.J. Blostein M.D. (2011) Fondaparinux in acute heparin-induced thrombocytopenia: a case series. J Thromb Haemost 9: 2501–2503.
23. Greinacher A. (2006) Heparin-induced thrombocytopenia: frequency and pathogenesis. Pathophysiol Haemost Thromb 35: 37–45.
24. Greinacher A. (2010) Opposites attract. Blood 115: 440–441.
25. Greinacher A. (2011) Immunogenic but effective: the HIT-fondaparinux brain puzzler. J Thromb Haemost 9: 2386–2388.
26. Greinacher A. Alban S. Omer-Adam M.A. Weitschies W. Warkentin T.E. (2008) Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res 122: 211–220.
27. Greinacher A. Farner B. Kroll H. Kohlmann T. Warkentin T.E. Eichler P. (2005) Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 94: 132–135.
28. Greinacher A. Gopinadhan M. Gunther J.U. Omer-Adam M.A. Strobel U. Warkentin T.E. et al. (2006) Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 26: 2386–2393.
29. Greinacher A. Michels I. Kiefel V. Mueller-Eckhardt C. (1991) A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost 66: 734–736.
30. Greinacher A. Mueller-Eckhardt G. (1993) Heparin-associated thrombocytopenia: no association of immune response with HLA. Vox Sang 65: 151–153.
31. Greinacher A. Potzsch B. Amiral J. Dummel V. Eichner A. Mueller-Eckhardt C. (1994) Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemost 71: 247–251.
32. Greinacher A. Warkentin T.E. (2006) Recognition, treatment, and prevention of heparin-induced thrombocytopenia: review and update. Thromb Res 118: 165–176.
33. Greinacher A. Warkentin T.E. (2008) The direct thrombin inhibitor hirudin. Thromb Haemost 99: 819–829.
34. Hankey G.J. Eikelboom J.W. (2011) Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 123: 1436–1450.
35. Hong A.P. Cook D.J. Sigouin C.S. Warkentin T.E. (2003) Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 101: 3049–3051.
36. Hopkins C.K. Goldfinger D. (2008) Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion 48: 2128–2132.
37. Hursting M.J. Pai P.J. McCracken J.E. Hwang F. Suvarna S. Arepally G.M. et al. (2010) Platelet factor 4/heparin antibodies in blood bank donors. Am J Clin Pathol 134: 774–780.
38. Hutchison C.A. Dasgupta I. (2007) National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant 22: 1680–1684.
39. Kelton J.G. Warkentin T.E. (1996) Heparin-induced thrombocytopenia: what the serologists have taught us. J Lab Clin Med 128: 346–348.
40. Kennedy K. Steinke D. King S. Poe K. Reeves J. (2011) Evaluation of a standardized protocol using lepirudin or argatroban for heparin-induced thrombocytopenia. Cardiovasc Hematol Agents Med Chem, in press, http://www.ncbi.nlm.nih.gov/pubmed/21902659.
41. Krauel K. Hackbarth C. Furll B. Greinacher A. (2011 a) Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood, in press, http://www.ncbi.nlm.nih.gov/pubmed/22049520.
42. Krauel K. Potschke C. Weber C. Kessler W. Furll B. Ittermann T. et al. (2011 b) Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia. Blood 117: 1370–1378.
43. Lindhoff-Last E. Piechottka G.P. Rabe F. Bauersachs R. (2000) Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res 100: 55–60.
44. Lo G.K. Juhl D. Warkentin T.E. Sigouin C.S. Eichler P. Greinacher A. (2006) Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4: 759–765.
45. Lubenow N. Eichler P. Lietz T. Farner B. Greinacher A. (2004) Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 104: 3072–3077.
46. Lubenow N. Hinz P. Thomaschewski S. Lietz T. Vogler M. Ladwig A. et al. (2010) The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 115: 1797–1803.
47. Lubenow N. Warkentin T.E. Greinacher A. Wessel A. Sloane D.A. Krahn E.L. et al. (2006) Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and / or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res 117: 507–515.
48. Ludwig R.J. Schindewolf M. Utikal J. Lindhoff-Last E. Boehncke W.H. (2006) Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thromb Haemost 96: 611–617.
49. Matsuo T. Kusano H. Wanaka K. Ishihara M. Oyama A. (2007) Heparin-induced thrombocytopenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin. Clin Appl Thromb Hemost 13: 182–187.
50. Matsuo T. Matuo M. Wanaka K. Sakai R. (2003) Heparin re-exposure after heparin-induced thrombocytopenia in a chronic hemodialysis patient. Clin Lab Haematol 25: 333–334.
51. Matsuo T. Wanaka K. (2008) Management of uremic patients with heparin-induced thrombocytopenia requiring hemodialysis. Clin Appl Thromb Hemost 14: 459–464.
52. Messmore H.L. Fabbrini N. Bird M.L. Choudhury A.M. Cerejo M. Prechel M. et al. (2011) Simple scoring system for early management of heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 17: 197–201.
53. Meyer O. Salama A. Pittet N. Schwind P. (1999) Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet 354: 1525–1526.
54. Moore J.C. Arnold D.M. Warkentin T.E. Warkentin A.E. Kelton J.G. (2008) An algorithm for resolving ‘indeterminate’ test results in the platelet serotonin release assay for investigation of heparin-induced thrombocytopenia. J Thromb Haemost 6: 1595–1597.
55. Pouplard C. Leroux D. Regina S. Rollin J. Gruel Y. (2010) Effectiveness of a new immunoassay for the diagnosis of heparin-induced thrombocytopenia and improved specificity when detecting IgG antibodies. Thromb Haemost 103: 145–150.
56. Prandoni P. Siragusa S. Girolami B. Fabris F. Group B.I. (2005 a) The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 106: 3049–3054.
57. Prandoni P. Tormene D. Pesavento R. and Vesalio Investigators Group (2005 b) High vs. low doses of low-molecular-weight heparin for the treatment of superficial vein thrombosis of the legs: a double-blind, randomized trial. J Thromb Haemost 3: 1152–1157.
58. Refaai M.A. Chuang C. Menegus M. Blumberg N. Francis C.W. (2010) Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost 8: 1419–1421.
59. Regnault V. de Maistre E. Carteaux J.P. Gruel Y. Nguyen P. Tardy B. et al. (2003) Platelet activation induced by human antibodies to interleukin-8. Blood 101: 1419–1421.
60. Rosenberger L.H. Smith P.W. Sawyer R.G. Hanks J.B. Adams R.B. Hedrick T.L. (2011) Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia. Crit Care Med 39: 833–838.
61. Sachs U.J. Sachs U.J. von Hesberg J. Santoso S. Bein G. Bakchoul T. (2011) Evaluation of a new nanoparticle-based lateral-flow immunoassay for the exclusion of heparin-induced thrombocytopenia (HIT). Thromb Haemost 106: 1197–1202.
62. Savi P. Chong B.H. Greinacher A. Gruel Y. Kelton J.G. Warkentin T.E. et al. (2005) Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 105: 139–144.
63. Schindewolf M. Kroll H. Ackermann H. Garbaraviciene J. Kaufmann R. Boehncke W.H. et al. (2010) Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost 8: 1486–1491.
64. Schindewolf M. Schwaner S. Wolter M. Kroll H. Recke A. Kaufmann R. et al. (2009) Incidence and causes of heparin-induced skin lesions. CMAJ 181: 477–481.
65. Selleng K. Schutt A. Selleng S. Warkentin T.E. Greinacher A. (2010 a) Studies of the anti-platelet factor 4/heparin immune response: adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. Transfusion 50: 32–39.
66. Selleng S. Haneya A. Hirt S. Selleng K. Schmid C. Greinacher A. (2008) Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood 112: 4024–4027.
67. Selleng S. Malowsky B. Itterman T. Bagemuhl J. Wessel A. Wollert H.G. et al. (2010 b) Incidence and clinical relevance of anti-platelet factor 4/heparin antibodies before cardiac surgery. Am Heart J 160: 362–369.
68. Socher I. Kroll H. Jorks S. Santoso S. Sachs U.J. (2008) Heparin-independent activation of platelets by heparin-induced thrombocytopenia antibodies: a common occurrence. J Thromb Haemost 6: 197–200.
69. Tholl U. Greinacher A. Overdick K. Anlauf M. (1997) Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. Nephrol Dial Transplant 12: 2750–2755.
70. Turun S. Banghua L. Yuan Y. Zhenhui L. Ying N. Jin C. (2011) A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. Thromb Res 127: 525–534.
71. van Os G.M. Meijers J.C. Agar Ç. Seron M.V. Marquart J.A. Akesson P. et al. (2011) Induction of anti-β (2)-glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J Thromb Haemost 9: 2447–2456.
72. Visentin G.P. Moghaddam M. Beery S.E. McFarland J.G. Aster R.H. (2001) Heparin is not required for detection of antibodies associated with heparin-induced thrombocytopenia/thrombosis. J Lab Clin Med 138: 22–31.
73. Wanaka K. Matsuo T. Matsuo M. Kaneko C. Miyashita K. Asada R. et al. (2010) Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. J Thromb Haemost 8: 616–618.
74. Warkentin T.E. (2003) Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121: 535–555.
75. Warkentin T.E. (2010) Fondaparinux: does it cause HIT? Can it treat HIT? Expert Rev Hematol 3: 567–581.
76. Warkentin T.E. Cook R.J. Marder V.J. Sheppard J.A. Moore J.C. Eriksson B.I. et al. (2005) Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106: 3791–3796.
77. Warkentin T.E. Davidson B.L. Buller H.R. Gallus A. Gent M. Lensing A.W. et al. (2011 a) Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE. Chest 140: 366–373.
78. Warkentin T.E. Greinacher A. (2004) Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl.): 311S-337S.
79. Warkentin T.E. Greinacher A. Koster A. (2008 a) Bivalirudin. Thromb Haemost 99: 830–839.
80. Warkentin T.E. Greinacher A. Koster A. Lincoff A.M. (2008 b) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl.): 340S-380S.
81. Warkentin T.E. Hayward C.P. Boshkov L.K. Santos A.V. Sheppard J.A. Bode A.P. et al. (1994 a) Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84: 3691–3699.
82. Warkentin T.E. Hayward C.P. Smith C.A. Kelly P.M. Kelton J.G. (1992) Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 120: 371–379.
83. Warkentin T.E. Hirte H.W. Anderson D.R. Wilson W.E. O'Connell G.J. Lo R.C. (1994 b) Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am J Med 97: 489–491.
84. Warkentin T.E. Kelton J.G. (2001 a) Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135: 502–506.
85. Warkentin T.E. Kelton J.G. (2001 b) Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344: 1286–1292.
86. Warkentin T.E. Pai M. Sheppard J.I. Schulman S. Spyropoulos A.C. Eikelboom J.W. (2011 b) Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost 9: 2389–2396.
87. Warkentin T.E. Sheppard J.A. (2006) Testing for heparin-induced thrombocytopenia antibodies. Transfus Med Rev 20: 259–272.
88. Warkentin T.E. Sheppard J.A. Sigouin C.S. Kohlmann T. Eichler P. Greinacher A. (2006) Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 108: 2937–2941.
89. Warkentin T.E. Sheppard J.I. Moore J.C. Sigouin C.S. Kelton J.G. (2008 c) Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays. J Thromb Haemost 6: 1304–1312.
90. Whitlatch N.L. Kong D.F. Metjian A.D. Arepally G.M. Ortel T.L. (2010) Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood 116: 1761–1766.
91. Whitlatch N.L. Perry S.L. Ortel T.L. (2008) Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 100: 678–684.
92. Williams R.T. Damaraju L.V. Mascelli M.A. Barnathan E.S. Califf R.M. Simoons M.L. et al. (2003) Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation 107: 2307–2312.
93. Ziporen L. Li Z.Q. Park K.S. Sabnekar P. Liu W.Y. Arepally G. et al. (1998) Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 92: 3250–3259.